Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02862067 · ClinicalTrials.gov registry record
SGLT2 Inhibition in Diabetes and Heart Failure
A clinical trial of Diabetes Mellitus, Type 2 and Heart Failure, Systolic, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- 18
- Enrollment target
- 1
- Study location
NCT02862067 is a study of Diabetes Mellitus, Type 2 and Heart Failure, Systolic that has completed, run by Virginia Commonwealth University. The registered enrollment target is 18 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02862067, a study of Diabetes Mellitus, Type 2 and Heart Failure, Systolic, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the effects of SGLT2 inhibition with empagliflozin on cardio-respiratory fitness in patients with systolic heart failure.
Conditions Studied
Interventions
- OTHER Assessment of cardiorespiratory fitness
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-07 |
| Est. Completion | 2018-01-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02862067
The ClinicalTrials.gov registry entry for NCT02862067 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (100% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Assessment of cardiorespiratory fitness is the first listed.
NCT02862067 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT02862067 about?
NCT02862067 is a clinical study titled "SGLT2 Inhibition in Diabetes and Heart Failure". To determine the effects of SGLT2 inhibition with empagliflozin on cardio-respiratory fitness in patients with systolic heart failure.
What is the current status of trial NCT02862067?
This trial is currently completed. The enrollment target is 18 participants. The study started on 2016-07. Estimated completion is 2018-01-16.
What conditions does trial NCT02862067 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Heart Failure, Systolic.
What interventions are being tested in trial NCT02862067?
The interventions under investigation include: Assessment of cardiorespiratory fitness (OTHER).
Who is sponsoring clinical trial NCT02862067?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02862067 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Drug Interaction Potential of Pro-Inflammatory Conditions
RECRUITING
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
RECRUITING · Phase 1
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.